Nvidia is teaming up with Abridge to develop a new artificial intelligence model for healthcare, The Wall Street Journal first reported Thursday.
The two technology companies said the AI model is designed for clinical conversations and will be used solely within Abridge’s platform to boost tasks such as clinical documentation and decision support, according to the WSJ.
Abridge and Nvidia each did not immediately respond to the Daily Caller News Foundation’s request for comment.
The new AI model will also be trained by Nvidia’s family of open models, dubbed Nemotron, Nvidia Vice President of Healthcare Kimberly Powell told the WSJ. Open-source AI refer to publicly accessible tools that anyone can use, modify and distribute, according to TedAI San Fransisco.
“There’s an opportunity now to take these models and adapt them with this clinical intelligence at a much earlier stage of model development,” Powell told the WSJ.
Nvidia is an Abridge investor, according to the WSJ. Abridge’s software “transforms patient-clinician conversations into contextually aware, clinically useful, and billable AI-generated notes,” according to the company’s website.
The WSJ’s report comes as a growing number of hospitals across the U.S. have begun relying on AI tools in recent years. A September 2025 report from the Office of the National Coordinator for Health IT found that 71% of hospitals reported using predictive AI integrated with the electronic health record in 2024, marking an increase from 66% in 2023.
Tampa General Hospital in Florida has slashed sepsis-related deaths by half by using advanced technology that continuously monitors patients to detect potential early warning signs, The Times reported on Tuesday.
All content created by the Daily Caller News Foundation, an independent and nonpartisan newswire service, is available without charge to any legitimate news publisher that can provide a large audience. All republished articles must include our logo, our reporter’s byline and their DCNF affiliation. For any questions about our guidelines or partnering with us, please contact [email protected].
